Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Mild Alzheimer's disease is the leading cause of dementia, accounting for 50–70% of cases.
Alzheimer's disease is an irreversible neurodegenerative disease, which affects daily life …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Astrocytes play key roles in the regulation of brain energy metabolism, which has a major
impact on brain functions, including memory, neuroprotection, resistance to oxidative stress …

Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and
more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and …

Aging is a natural process, which plays a critical role in the pathogenesis of a variety of
diseases, ie, aging-related diseases, such as diabetes, osteoarthritis, Alzheimer disease …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

Common chronic diseases represent the greatest driver of rising healthcare costs, as well as
declining function, independence, and quality of life. Geroscience‐guided approaches seek …

Metformin is one of the most widely prescribed hypoglycemic drugs and has the potential to
treat many diseases. More and more evidence shows that metformin can regulate the …

Aims/hypothesis Metformin use has been associated with reduced incidence of dementia in
diabetic individuals in observational studies. However, the causality between the two in the …